Tvardi Therapeutics, Inc. (TVRD) — SEC Filings
Tvardi Therapeutics, Inc. (TVRD) — 49 SEC filings. Latest: 10-Q (May 8, 2026). Includes 26 8-K, 7 10-Q, 4 SC 13G/A.
View Tvardi Therapeutics, Inc. on SEC EDGAR
Overview
Tvardi Therapeutics, Inc. (TVRD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 18, 2025: Tvardi Therapeutics, Inc. announced on December 16, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Jonathan Lim and Mr. David J. E. Johnson, and appointed Mr. Michael J. McVicar as Chief Medical Officer. The filing also de
Sentiment Summary
Across 49 filings, the sentiment breakdown is: 1 bullish, 6 bearish, 40 neutral, 2 mixed. The dominant filing sentiment for Tvardi Therapeutics, Inc. is neutral.
Filing Type Overview
Tvardi Therapeutics, Inc. (TVRD) has filed 7 10-Q, 26 8-K, 1 DEFA14A, 1 S-8, 1 424B3, 2 S-1/A, 1 S-1, 2 8-K/A, 2 10-K, 1 SC 13D, 4 SC 13G/A, 1 DEF 14A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (49)
Risk Profile
Risk Assessment: Of TVRD's 34 recent filings, 6 were flagged as high-risk, 15 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$10.9M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $36.5M |
| Operating Margin | N/A |
| Total Assets | $39.0M |
| Total Debt | $11.2M |
Key Executives
- Dr. Jonathan Lim
- Mr. David J. E. Johnson
- Mr. Michael J. McVicar
- Imran Alibhai
- Dr. Robert Y. Yu
- Tinne Gilles
- Dr. Joana Neves
- Dr. Christopher Gallen
- Christopher Coughlin
Industry Context
The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Tvardi Therapeutics focus on developing novel therapies for unmet medical needs, often in competitive therapeutic areas. Success is heavily dependent on clinical trial outcomes and subsequent regulatory approvals.
Top Tags
financials (7) · acquisition (6) · pharmaceuticals (5) · 8-K (4) · financial-reporting (4) · 10-Q (4) · merger (4) · Biopharmaceutical (3) · Clinical Stage (3) · Going Concern (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $10.9M | for the nine months ended September 30, 2025, an improvement from $16.69M in 2024 |
| Cash Used in Operating Activities | $17.8M | for the nine months ended September 30, 2025, indicating significant burn |
| Accumulated Deficit | $103.2M | as of September 30, 2025, highlighting historical losses |
| Cash and Cash Equivalents | $21.4M | as of September 30, 2025, including $23.9M from merger |
| Research and Development Expenses | $12.52M | for the nine months ended September 30, 2025, a decrease from $15.05M in 2024 |
| General and Administrative Expenses | $6.64M | for the nine months ended September 30, 2025, a significant increase from $2.26M in 2024 |
| Common Shares Outstanding | 9,381,344 | as of November 10, 2025, reflecting post-merger share structure |
| Net Assets Acquired | $23.9M | from the Merger Agreement in April 2025 |
| Reverse Stock Split Ratio | 1-for-3 | Cara Therapeutics effected a 1-for-3 reverse stock split of its common stock on April 15, 2025. |
| Authorized Shares of Common Stock | 150,000,000 | Cara Therapeutics increased its authorized shares of common stock to 150,000,000 on April 15, 2025. |
| Shares Issued Post-Merger | 7,805,161 | Tvardi issued 7,805,161 shares of common stock to Legacy Tvardi stockholders and convertible note holders. |
| Total Shares Outstanding Post-Merger | 9,355,542 | There were 9,355,542 shares of common stock issued and outstanding immediately following the merger. |
| Shares for Resale | 2,084,117 | Selling stockholders are offering up to 2,084,117 shares of common stock for resale. |
| Last Quoted Sale Price | $6.58 | On October 17, 2025, the last quoted sale price for TVRD common stock on Nasdaq was $6.58. |
| Merger Closing Date | April 15, 2025 | The merger between Cara Therapeutics and Legacy Tvardi closed on April 15, 2025. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Tvardi Therapeutics, Inc. (TVRD)?
Tvardi Therapeutics, Inc. has 49 recent SEC filings from Jan 2024 to May 2026, including 26 8-K, 7 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TVRD filings?
Across 49 filings, the sentiment breakdown is: 1 bullish, 6 bearish, 40 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Tvardi Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Tvardi Therapeutics, Inc. (TVRD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Tvardi Therapeutics, Inc.?
Key financial highlights from Tvardi Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TVRD?
The investment thesis for TVRD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Tvardi Therapeutics, Inc.?
Key executives identified across Tvardi Therapeutics, Inc.'s filings include Dr. Jonathan Lim, Mr. David J. E. Johnson, Mr. Michael J. McVicar, Imran Alibhai, Dr. Robert Y. Yu and 4 others.
What are the main risk factors for Tvardi Therapeutics, Inc. stock?
Of TVRD's 34 assessed filings, 6 were flagged high-risk, 15 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Tvardi Therapeutics, Inc.?
Forward guidance and predictions for Tvardi Therapeutics, Inc. are extracted from SEC filings as they are enriched.